Position of the Transparency Council – Calquence (acalabrutinib)

At its meeting on 9 September 2024, the Transparency Council adopted position No. 92/2024 on the evaluation of the drug Calquence (acalabrutinib) under the drug program: treatment of patients with chronic lymphocytic leukemia (ICD-10: C91.1).

Publication of the position >>